Actively Recruiting
Post Market Study Evaluating the Safety and Performance of the PRESERFLO MicroShunt XI Device in Adults with Primary Open Angle Glaucoma
Led by Santen SAS · Updated on 2026-10-28
112
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting safety and performance data on the PRESERFLO MicroShunt XI device in patients with primary open angle glaucoma whose intraocular pressure IOP is not adequately controlled despite maximum tolerated medical therapy. This study focuses on patients with IOP between 18 and 35 mmHg or those whose glaucoma progression requires surgery. The study is a prospective, multicenter, single-arm post-market follow-up to evaluate this CE-marked device designed for glaucoma treatment. The PRESERFLO MicroShunt XI is a small implantable device that creates a passageway to drain aqueous humor from the eyes anterior chamber to a bleb beneath the conjunctiva, helping to reduce eye pressure. The device is surgically implanted by trained ophthalmologists or surgeons specializing in glaucoma or anterior segment surgery. There is no control group, and no biospecimens are collected as part of this study. Participants will undergo surgical implantation of the MicroShunt XI and be followed over time to monitor safety and performance. Researchers will assess changes in intraocular pressure up to 12 months after surgery. No additional ocular surgeries are planned during the study period. The study includes regular visits to evaluate eye health, monitor adverse events, and collect performance data, with participant involvement lasting up to 12 months.
CONDITIONS
Brief Title
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Research Team
S
Study Director / Medical Monitor Raymund Angeles
S
Santen SAS Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here